These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 29214842)

  • 1. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
    Doroshow DB; LoRusso PM
    Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T; Teuwen LA; Rutten A; Dirix L
    Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
    LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
    Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K
    Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab emtansine in breast cancer.
    Dirix LY; Rutten A; Huget P; Dirix M
    Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
    Lambert JM; Chari RV
    J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.
    Diéras V; Bachelot T
    Target Oncol; 2014 Jun; 9(2):111-22. PubMed ID: 23852665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
    Guerin M; Sabatier R; Gonçalves A
    Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
    Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
    Dhillon S
    Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.